Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03569007 · ClinicalTrials.gov registry record · Phase 3
Study to Evaluate the Efficacy and Safety of Larazotide Acetate for the Relief of CeD Symptoms
A Phase 3 study, sponsored by 9 Meters Biopharma.
- Terminated
- Registry status
- Phase 3
- Development phase
- 307
- Enrollment target
NCT03569007: Clinical Trial Phase 3 study, sponsored by 9 Meters Biopharma.
NCT03569007 is a Phase 3 study that was terminated before completion, run by 9 Meters Biopharma. The registered enrollment target is 307 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (60% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03569007, a Phase 3 study, was terminated before completion, sponsored by 9 Meters Biopharma.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 307 participants
- Enrollment target
Study Summary
To assess the efficacy and safety of larazotide acetate versus placebo for the relief of persistent symptoms in adult celiac disease patients.
Primary Outcome
Reduction in CeD PRO Abdominal Domain scores
Interventions
- DRUG Matching Placebo
- DRUG Larazotide
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 307 participants |
| Start Date | 2019-05-29 |
| Est. Completion | 2022-07-21 |
| Phase | Phase 3 |
Why NCT03569007 stopped before completion
NCT03569007 is an interventional study that assigns participants to a tested intervention. The registered 307 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (60% lower).
The record links to 0 conditions, and to 2 interventions - of which Matching Placebo is the first listed.
NCT03569007 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03569007 about?
NCT03569007 is a clinical study titled "Study to Evaluate the Efficacy and Safety of Larazotide Acetate for the Relief of CeD Symptoms". To assess the efficacy and safety of larazotide acetate versus placebo for the relief of persistent symptoms in adult celiac disease patients.
What is the current status of trial NCT03569007?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 307 participants. The study started on 2019-05-29. Estimated completion is 2022-07-21.
What interventions are being tested in trial NCT03569007?
The interventions under investigation include: Matching Placebo (DRUG), Larazotide (DRUG).
Who is sponsoring clinical trial NCT03569007?
This trial is sponsored by 9 Meters Biopharma, which has 9 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03569007's enrollment target sits among peer trials
307 1115th of 2000 higher than 886 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05433142 · 307 participants · Phase 1
Study of XmAb®819 in Subjects With Advanced Clear Cell Renal Cell Carcinoma
- NCT04162938 · 308 participants · NA
Use of a Patient-Centered Electronic App to Increase ED Patient's Knowledge on HCV to Improve the HCV Care Continuum
- NCT04955795 · 308 participants · NA
Telemedicine for Unhealthy Alcohol Use in Persons Living With HIV Using CETA
- NCT06090539 · 308 participants · Phase 1
A Study to Assess BMS-986458 Alone and in Combination With Anti-lymphoma Agents in Relapsed/Refractory Non-Hodgkin Lymphomas
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI